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The viral strain responsible for smallpox infection is variola major (VARV). As a result of the successful eradication of smallpox with the
vaccinia virus (VACV), the general population is no longer required to receive a smallpox vaccine, and will have no protection against smallpox.
This lack of immunity is a concern due to the potential for use of smallpox as a biological weapon. Considerable progress has been made in the
development of subunit-based smallpox vaccines resulting from the identification of VACV protective antigens. It also offers the possibility of
using antigens from VARV to formulate the next generation subunit-based smallpox vaccines. Here, we show that codon-optimized DNAvaccines
expressing three VARV antigens (A30, B7 and F8) and their recombinant protein counterparts elicited high-titer, cross-reactive, VACV
neutralizing antibody responses in mice. Vaccinated mice were protected from intraperitoneal and intranasal challenges with VACV. These results
suggest the feasibility of a subunit smallpox vaccine based on VARV antigen sequences to induce immunity against poxvirus infection.
© 2007 Elsevier Inc. All rights reserved.Keywords: Variola major; Vaccinia virus; Smallpox; Subunit vaccineIntroduction
The original smallpox vaccine, based on the live attenuated
vaccinia virus (VACV), eradicated smallpox from the worldwide
human population with the last case of natural smallpox
infection occurring in Somalia in 1977 (WHO, 1980). However,
due to safety concerns over the manufacture of the traditional
VACV vaccine, the production of this type of vaccine, such as
DryVax (Wyeth Laboratories, Inc.) in the United States and
derived from the NYCBH strain of vaccinia virus, is no longer
considered acceptable since termination of its production in
1982. Reports of adverse events including myocarditis that are
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doi:10.1016/j.virol.2007.09.029have prevented the completion of a 2002 re-vaccination cam-
paign among non-military high-risk populations, such as
healthcare professionals. Currently, VACV is still the main
smallpox vaccine and a newer generation of live-attenuated
VACV vaccines is being produced in tissue cultured cells to
allow for stockpiling in hopes of being able to protect the general
population in the event of a bioterrorist attack (Artenstein et al.,
2005; Fang et al., 2006; Monath et al., 2004).
Recent studies have made great strides in demonstrating the
use of subunit-based smallpox vaccines to induce protective
immunity against smallpox. Poxviruses, which include variola
major (VARV), vaccinia virus (VACV), monkeypox virus,
ectromelia virus (ECTV) and others, belong to the orthopox-
virus genus and considerable cross-protection has been observed
between these viruses. Poxviruses are large viruses with a
genome that encodes about 200 proteins and it is this complexity
which has partly delayed the identification of protective antigens
against these viruses. Several potential targets of protective
immunity have only recently been confirmed in well organized
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intracellular mature virus (IMV) and the extracellular enveloped
virus (EEV). Recent studies have shown that vaccinia virus
IMV-specific antigens, A27, L1 and D8, and EEV-specific
antigens, A33 and B5, are immunogenic and protective, albeit
variably, against VACV infection in mice (Fogg et al., 2004;
Galmiche et al., 1999; Hooper et al., 2000, 2004; Pulford et al.,
2004; Sakhatskyy et al., 2006; Xiao et al., 2007), against
ectromelia virus (ECTV) (Xiao et al., 2007) and against
monkeypox in non-human primates (Heraud et al., 2006;
Hooper et al., 2004). Furthermore, a four-gene combination
DNAvaccine that encodes two IMV (A27 and L1) and two EEV
(A33 and B5) antigens was protective against vaccinia virus
challenge in mice and induced antibody responses against
monkeypox virus in non-human primates (Hooper et al., 2003).
However, these subunit vaccines were not as protective as the
live-attenuated vaccinia virus vaccine unless polyvalent for-
mulations and/or multiple immunizations are used to achieve
comparable levels of protection inducible by one single vaccinia
inoculation (Fogg et al., 2004; Hooper et al., 2000, 2003; Pulford
et al., 2004; Sakhatskyy et al., 2006).
Why the live-vaccinia virus vaccine offers better protection
against infection is unclear and studies have been conducted to
examine the contributions of the two arms of the immune system
in offering protective immunity against poxvirus infection by
depletion of B- and T-cells prior to primary and/or secondary
challenge with various poxviruses, offering conflicting results.
Antibody-mediated depletion of B-cells, but not of CD4+ or
CD8+ T-cells, prevented vaccine-induced protection from a
lethal intravenous challenge with monkeypox virus (Edghill-
Smith et al., 2005) and poxvirus in a mouse model (Belyakov
et al., 2003) indicating that this protective response is primarily
mediated by antibodies and that vaccinia-induced antibodies are
necessary and sufficient for protection against a lethal poxvirus
challenge. Additional results confirming the role of antibody
responses show that passive administration of VACVantibodies
confers protection from subsequent lethal monkeypox (Edghill-
Smith et al., 2005; Hooper et al., 2004) and that type I/II IFN
deficient, CD8+ depleted mice were able to survive a secondary
infection with ECTV (Panchanathan et al., 2005). However, to
determine immune responses in primary and secondary
vaccination against smallpox in humans, a recent study has
shown that positive CMI responses could be elicited 7 days after
infection in secondary immunized volunteers (i.e., vaccinia non-
naive) and that this response preceded increases in antibody
titers (Kennedy et al., 2004). Furthermore, an important role for
interferon (IFN) and less of a role for antibodies in conferring
protection against poxvirus was observed following a primary
infection (Panchanathan et al., 2005; Pulford et al., 2004). While
the exact roles of each arm of the immune system in mediating
poxvirus infection have not been completely elucidated, the
majority of recent reports point to a greater role of antibodies
against various poxvirus antigens in eliciting protection against
poxvirus infection. Therefore, it appears as though subunit-
based smallpox vaccines that induce poxvirus-specific anti-
bodies would be effective in conferring protection from poxvirus
infection.Although poxviruses are highly conserved in the regions that
encode protective antigens, it is not clear whether antibodies
induced by variola antigens may confer a higher level of
protection against homologous challenge when compared to
those responses induced by vaccinia antigens. A recent study
examining the differences between the major neutralizing B5
antigenic site on vaccinia virus and its variola virus ortholog B6
demonstrated that from a panel of 26 anti-B5 monoclonal
antibodies only 16 cross-reacted with B6 protein and out of 10
that did not at least 3 were EEV neutralizing or blocked comet
formation (Aldaz-Carroll et al., 2007). These results indicate
that the production of a subunit-based vaccine using VARV
antigens rather than those from VACV may confer greater
protection against smallpox infection and there is no apparent
reason not to use VARVantigens with a subunit-based vaccine.
While safety issues over using the variola virus itself as a live
attenuated vaccine lead to the use of antigens from the vaccinia
virus, the production of a subunit-based vaccine does not
incorporate live viruses into its design and therefore eliminates
the safety concerns over using variola virus antigens. The goal
of this current study was to demonstrate the feasibility of
producing a subunit smallpox vaccine based on VARV antigen
sequences. At least in theory, this approach should minimize the
chance of reduced protection due to any sequence difference
that may exist between VARV and VACV, particularly when
antigen-specific immune responses, such as neutralizing
antibody determinants and/or dominant T-cell epitopes, are
involved. In the current study, three VARV antigens (A30, B7
and F8) were chosen based on the high immunogenicity and
potential of protection from their VACV counterparts (A27, B5
and D8) as shown in the literature and from our recently
published studies (Sakhatskyy et al., 2006).
Results
Sequence homology between variola major and vaccinia
protective antigens
Amino acid sequences of three well-characterized protective
antigens (A27, B5 and D8) from VACV were compared with
orthologous proteins from the VARV virus (Fig. 1). For VACV
sequences, two frequently used strains, Western Reserve (WR)
and Copenhagen (COP), were included for the analysis. For
VARV, the India 1967 (VARV-IND) and Bangladesh 1975
(VARV-BSH) strain sequences were used. The orthologous
VARV protein for the VACVA27 antigen is A30 for VARV-IND
and A31 for VARV-BSH; for the B5 antigen the orthologous
protein is B7 for VARV-IND and B6 for VARV-BSH, and for
the D8 antigen the orthologous protein for both VARV-IND and
VARV-BSH is F8 (Shchelkunov, 1995; Shchelkunov et al.,
1995). Sequences of these three proteins are highly homologous
but not completely identical to the VACV antigen sequences:
three amino acid differences exist between A27 and A30/A31,
23 amino acid differences between B5 and B6/B7 and 12 amino
acid differences between D8 and F8 proteins (Fig. 1). Some of
these differences occurred with only one of the two VARV
strains, thereby further improving the overall level of homology.
Fig. 1. Sequence analysis of the selected protective variola major and vaccinia antigens. Amino acid sequences of the proteins encoded by the WR and COP strains of
the vaccinia virus and those encoded by variola India 1967 and Bangladesh 1975 were compared. The numbers at the top are amino acid positions. Amino acids that
were different between these strains are shown in bold, and amino acids that are not shown but identical in all viruses are presented as dots.
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recombinant A30, F8 and B7 by an E. coli expression system
The codon modified A30L, B7R and F8L genes of VARV-
IND were chemically synthesized without the involvement of
actual variola virus. Although the final codons did not change
what amino acids were coded, this procedure increases the
frequency of codons that are used by mammalian cells and has
been shown to potentially improve antigen expression and
immunogenicity of DNA vaccines (Haas et al., 1996; Wang
et al., 2006). Then the synthetic genes coding for the VARV
A30, F8 or B7 proteins were individually cloned into the DNA
vaccine vector pSW3891, which uses a CMV IE promoter to
drive the expression of the coded antigen insert (Wang et al.,Fig. 2. Western blot analysis of transiently expressed A30, F8 and B7 proteins from t
respective variola major antigen-expressing DNA vaccine (A30L, F8L or B7R). Rec
included in the analysis. Vaccinia WR strain, grown in Vero cells, is included as a po
The B7 proteins, which were glycosylated when expressed in 293T or Vero cells, w2005). In addition, they were all placed behind a human tissue
plasminogen activator (tPA) leader sequence which was shown
to be effective in improving the antigen expression and antigen
immunogenicity for DNA vaccines (Wang et al., 2006). A30
and F8 DNA vaccines encode for the full-length proteins while
B7 DNA vaccine expresses the ectodomain of B7 because the
full-length B7 DNA vaccine does not achieve a good antigen
expression (data not shown).
Expression of these codon-optimized VARV antigen DNA
vaccines was verified in culture supernatants and cell lysates
from 293T cells transiently transfected with each of the three
VARV antigen DNA plasmids and examined by Western blot
using a polyclonal anti-vaccinia virus serum (Fig. 2). All three
antigens were present in both the cell lysate (L) and culturehe cell lysate (L) and culture supernatant (S) of 293T cells transfected with their
ombinant variola major proteins rA30, rB7 and rF8 produced in E. coli are also
sitive control. The empty DNA vaccine vector is included as a negative control.
ere subjected to PNGase treatment.
Fig. 3. Recognition of variola major and vaccinia antigens by ELISA using the same polyvalent mouse serum induced with the combination of three DNA vaccines
expressing variola major antigens A30, B7 and F8. Each curve is the average of sera assayed from 10 mice that have received three monthly immunizations. Each panel
shows one pair of ortholog antigens from both variola and vaccinia.
Fig. 4. Neutralizing antibody activities against the vaccinia intracellular mature
virus (IMV) as measured by the plaque reduction test. Sera were collected from
BALB/c mice after 3 monthly immunizations with DNA vaccines expressing
either individual vaccinia antigens (A27L and D8L) or individual variola
antigens (A30L and F8L). Sera from mice immunized with VACV served as a
positive control. Sera from the group that received an empty DNA vaccine
vector were used as the negative control. Data are shown as average titers from
10 mice per group.
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those from the VACV-WR strain grown in Vero cells, except for
the B7 DNA vaccine which only expresses a smaller molecular
weight ectodomain of B7 protein. The apparent molecular
weight of B7 antigen in lysate was slightly larger than B7 in
supernatant—indicating additional post-translational processing
of B7 protein as an intermediate product prior to secretion. Non-
transfected 293T cells and uninfected Vero cells did not show
pox-specific antigens (Fig. 2). In addition, we show that
recombinant A30, B7 and F8 proteins (rA30, rF8 and rB7)
were successfully produced and purified from an E. coli
expression system using the same synthetic A30, B7 and F8
genes (Fig. 2). These results also show that the B7 protein forms
dimers in its non-denatured condition. According to sequence
analysis, the B7 protein has potential sites for N-glycosylation
which was confirmed by its sensitivity to PNGase treatment
(Fig. 2).
Immunogenicity of the A30, F8 and B7 DNA vaccines
Three monthly immunizations with VARV DNA vaccines
elicited high levels of antigen-specific IgG antibody responses in
mice (Fig. 3). The immunogenicity of each DNA vaccine is
slightly different: A30 being the most immunogenic, followed
by the F8 and B7 DNA vaccines. Antibodies induced by
immunization with codon optimized variola DNA vaccines
recognized both vaccinia and variola antigens expressed in the
supernatant of transiently transfected 293T cells. Given the
polyclonal nature of the immune sera, it was not surprising that
we did not detect a significant difference in recognition of
variola or vaccinia antigens by ELISA (Fig. 3).
Immunization with DNA vaccines, expressing the two
individual VARV IMV antigens, F8 and A30, produced anti-
bodies that were able to neutralize VACV in a plaque reduction
assay that measures IMV antibodies (Fig. 4). The levels of
neutralizing antibodies were similar to immune sera elicited by
their individual VACV counterparts, D8 and A27. Similar to the
previous report with VACV IMV antigens (Sakhatskyy et al.,
2006), the subunit VARV IMVantigens were more effective than
an intact vaccinia infection in eliciting IMV neutralizing
antibodies in the current study.Protection efficacy of VARV DNA vaccines expressing A30, F8
and B7 antigens against lethal VACV challenges in mice
We tested the ability of mono- and polyvalent DNAvaccines
that expressed VARV antigens to induce protection in two
VACV challenge models. In the first challenge study, mice first
received three monthly DNA immunizations, rested for 1 month
and received another boost 2 weeks prior to challenge to ensure
a complete protection in this pilot study. Mice were inoculated
intraperitoneally (i.p.) with a lethal dose (5×107 pfu) of VACV
(WR). VARV antigen-specific antibodies after 1, 2 or 3
monovalent DNA vaccine inoculations were measured by
ELISA (Fig. 5A). DNA vaccines expressing each of the three
VARV antigens induced high titers of antibodies after the 2nd
immunization and additional DNA vaccination was not needed
Fig. 5. Variola antigen-specific antibody responses and protection against lethal intraperitoneal (i.p.) VACV challenge in BALB/c mice immunized with DNAvaccines
expressing variola antigens. (A) ELISA analysis of end titration IgG titers of mouse sera immunized with monovalent DNAvaccines expressing either A30, B7 or F8
against the autologous antigens expressed in 293T cells. Sera were collected after one, two or three monthly DNA immunizations. The data are shown as the geometric
mean titers of 5 animals. (B) Protection against i.p. VACV challenge in mice immunized with either the monovalent or the combination of A30L, B7R and F8L DNA
vaccines. Mice immunized with either the positive control vaccinia (WR) or the negative control empty DNA vaccine vector are also included. Body weight loss,
shown as the percentage of pre-challenge weight, was measured daily. Each curve shows the group average weight loss (5 mice per group) after challenge.
(C) Protection against i.p. VACV challenge in mice immunized with either combination of vaccinia DNA vaccines (A27L, B5R and D8L) or combination of variola
DNAvaccines (A30L, B7R and F8L) or an empty DNAvaccine vector as the negative control. Body weight loss, shown as the percentage of pre-challenge weight, was
measured daily. Each curve shows the group average weight loss±standard deviation (5 mice per group) after challenge.
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an indicator of protection against lethal VACV in this i.p.
challenge model, average weight loss of the surviving mice in
each group was measured (Fig. 5B). All negative control mice
inoculated with the DNA vector progressively lost weight and
died by Day 5. Mice that received either the mono- or
polyvalent VARV DNA vaccines survived the challenge and
regained body weight. Mice that received the polyvalent VARV
DNAvaccine recovered back to their initial body weight sooner
than mice that received any of the monovalent DNA vaccines
(Fig. 5B). The polyvalent VARV and polyvalent VACV
formulations were able to achieve similar levels of protection
(Fig. 5C).
Although intraperitoneal VACV challenge leads to lethal
poxvirus infection, it does not represent the natural aerosol
spread of the virus. The intranasal method of infection requires
significantly less virus to produce a lethal infection and causes
death at a later time point suggesting a different virus–host
interaction. In addition, the intranasal mode of infection
represents a more stringent challenge model (Sakhatskyy
et al., 2006). Therefore, we investigated the efficacy of
protection when subunit-based VARV antigens were deliveredin the form of DNA or recombinant protein vaccines in an
intranasal challenge model.
In this intranasal challenge study, groups of mice received
2 bi-weekly immunizations of either a polyvalent rA30, rB7 and
rF8 recombinant protein vaccine or a polyvalent DNA vaccine
expressing the A30, B7 and F8 antigens (Fig. 6). The number of
immunizations was reduced to two based on the excellent
immune responses after two immunizations as shown in the i.p.
challenge studies (Fig. 5). Mice immunized with the vaccinia
vaccine served as a positive control, and the negative control
group received only empty DNA vector (Fig. 6). Antigen-
specific antibodies induced by either the DNA or protein
formulations and immunizations with vaccinia vaccine were
analyzed by ELISA (Fig. 6A). Immunization with the polyvalent
recombinant VARV protein vaccines was significantly more
immunogenic than immunization with the polyvalent VARV
DNAvaccines (pb0.01) (Fig. 6A) based on ELISA results. The
protein vaccine was even more immunogenic than the live
vaccinia vaccine in generating specific antibodies against three
tested pox antigens. In contrast, immunization with the
polyvalent DNA-based VARV vaccines induced only margin-
ally higher antibody responses when compared to immunization
Fig. 6. Immunogenicity and protection efficacy of polyvalent recombinant
variola protein vaccines and polyvalent DNA vaccines expressing variola
antigens. (A) ELISA analysis of end titration IgG titers against A30, B7 or F8
antigens in immunized mice sera. Data are shown as the geometric mean titers of
each group (5 per group) after two bi-weekly immunizations. Animals were
immunized with either a combination of recombinant A30, B7 and F8 proteins
(Protein), or a combination of three DNA vaccines expressing A30, B7 and F8
antigens (DNA). Control group animals received a one-time vaccinia (WR)
immunization (VACV). The protein immunization elicited significantly higher
antibody when compared to DNA immunization (⁎ indicates pb0.01).
(B) Protection against a lethal intranasal challenge of VACV (WR) in mice
that received two bi-weekly immunizations of either the combination of three
recombinant variola proteins (rA30, rB7 and rF8) or the combination of three
DNA vaccines expressing A30, B7 and F8. Positive control animals received a
one-time vaccinia (WR) immunization and negative control animals received
three immunizations of an empty DNA vaccine vector. Each curve shows the
daily percentage of survivals for each group (5 mice per group) after challenge.
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occurred as a result of very low anti-B7 antibody responses in
VACV immunized mice.
Mice were challenged with a lethal intranasal dose of VACV
(WR) (5×106 pfu) 2 weeks after the 2nd immunization. While
all mice in the control group died by Day 11 (Fig. 6B), mice that
received either the polyvalent recombinant VARV proteinvaccination or the vaccinia vaccine immunization were fully
protected, as indicated by a 100% survival rate following the
intranasal challenge (Fig. 6B). Two immunizations with the
polyvalent DNAvaccine induced partial protection with 4 out of
5 mice surviving by Day 14 (Fig. 6B). Both protein and DNA
subunit vaccine formulations induced statistically significant
greater levels of protection when compared to the vector control
group (p=0.0017 and p=0.0211, respectively), as determined
by a Kaplan–Meier survival test.
Discussion
Over the past few years, progress has been made which
establishes the use of subunit-based smallpox vaccines
delivered in the form of DNA plasmids (Hooper et al., 2000,
2003, 2007, 2004; Pulford et al., 2004; Sakhatskyy et al., 2006)
or recombinant proteins (Davies et al., 2005; Fang et al., 2006;
Fogg et al., 2004; Galmiche et al., 1999; Heraud et al., 2006;
Xiao et al., 2007) to induce antibodies and/or protection against
poxvirus infection. This has been made possible through the
identification of the immunogenic and protective vaccinia virus
IMV-specific antigens (e.g., A27, L1 and D8) and EEV-specific
antigens (e.g., A33 and B5). These antigens have shown to be
immunogenic and protective against VACV infection in mice
(Fogg et al., 2004; Galmiche et al., 1999; Hooper et al., 2000,
2004; Pulford et al., 2004; Sakhatskyy et al., 2006; Xiao et al.,
2007), against ectromelia virus (ECTV) (Xiao et al., 2007) and
against monkeypox virus in non-human primates (Heraud et al.,
2006; Hooper et al., 2004). Despite this great progress, these
previous studies used antigen genes cloned from VACV or
monkeypox virus rather than those from VARV to induce broad
and protective antibody responses mainly due to safety concerns
over using VARV as a model and to the difficulty in producing
VARV infection in species other than humans and some non-
human primates. Although the sequences are very similar
between these viruses (i.e., VACV or monkeypox virus) and
VARV, they are not completely identical. In a recent study, the
properties of the vaccinia virus EEV protein B5 and its Variola
ortholog B6 were compared in order to determine whether B6 is
a better choice as a subunit vaccine against smallpox. This study
found that from a panel of 26 anti-B5 monoclonal antibodies
only 16 cross-reacted with B6 protein and out of the 10 that did
not, at least 3 were EEV neutralizing or blocked comet for-
mation (Aldaz-Carroll et al., 2007). With current technology, it
has become possible to produce synthetic gene sequences based
on the known VARV protein sequences, which may be more
immunologically desirable in producing immune responses
against smallpox infection than the genes from another pox
virus. It could be argued that VARV-based antigens should be
more compatible with the invading smallpox infection than
VACV antigens although the definitive proof can only be
obtained in a VARV challenge study which is not readily
available due to security control of VARV reagents.
In the current study, we produced subunit-based smallpox
vaccines that are based on the three VARV protective antigens,
A30, B7 and F8, which are orthologous of the IMVantigens A27
and D8 and the EEVantigen B5 from VACV. The sequences of
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with the VACV antigen sequences, as only three amino acid
differences exist between A27 and A30, 23 amino acid
differences between B5 and B7 and 12 amino acid differences
between D8 and F8. While these VACV antigens have been
shown to elicit a good level of protection from intranasal VACV
challenge (Pulford et al., 2004), there have been no reports
showing whether DNA or recombinant protein vaccines based
on the VARV protective antigens are able to induce neutralizing
antibodies and protection against VACV.
Here, we show that immunization with codon optimized
monovalent DNA vaccines that express the F8 and A30 VARV
antigens elicited antibodies that were able to neutralize VACV, as
measured in a plaque reduction assay. Furthermore, when these
VARV antigens were given in combination, they induced neu-
tralizing responses similar to those produced by their VACV
counterparts, D8 and A27, when administered in combination
(data not shown). This increase in immunogenicity after
administration of a combination of antigens compared to when
administered as a monovalent formulation is consistent with
studies done with VACV antigens. Immunization with DNA
vaccines encoding for a single VACV membrane protein induced
only modest anti-VACV reactivity (Pulford et al., 2004) as
compared to when these antigens were given in combination
(Hooper et al., 2000, 2003). Mice that were vaccinated with
polyvalent (i.e., A30, F8 and B7) VARV antigen DNA vaccines
were protected from intraperitoneal challenge. When the VACV
challenge was administered intranasally, mice that were immu-
nized with either the polyvalent recombinant protein or DNA
vaccines were protected. Furthermore, we observed that with only
two immunizations, the protein-based subunit vaccine was more
effective thanDNAvaccines in eliciting higher antibody responses
and better protection in the dose ranges tested in the current study
with the adjuvant used for protein immunization. Since the current
study was not designed to compare the difference between DNA
and protein-based VARV vaccines, more dedicated studies,
especially in non-human primates, are needed to further identify
any qualitative and quantitative differences in immunogenicity and
protective efficacy for these two types of VARV vaccines.
In summary, a vaccine based on antigens from the VARV virus
can confer protective immunity against both intranasal and
intraperitoneal challenge with the vaccinia virus and induce
neutralizing antibodies against VACV. Given the decreased cross-
reactivity of anti-B5 VACVantigens with B6 antigens of variola
major (Aldaz-Carroll et al., 2007), our study demonstrated that it
is feasible that a variola major antigen-based vaccine can be
produced and may potentially confer more matched immune
responses and/or greater protection following exposure to VARV.
Results from this study show that there is no apparent advantage
of substituting original VARV antigens for their orthologs from
less virulent poxviruses, as indicated by the similar levels of
neutralizing antibodies and levels of protection against VACV
challenge between the VARVantigen-based vaccines, developed
in this study, and the orthologous VACV antigens. Results from
the current study suggest that future efforts in the development of
subunit-based smallpox vaccines may be better suited to focus on
optimizing the conditions necessary to elicit immunologicalresponses from the variola major protective antigens themselves
rather than those from the vaccinia virus.
Materials and methods
Viruses and cells
Western Reserve strain of vaccinia virus (VACV-WR)
provided by Dr. Lisa Selin from University of Massachusetts
Medical School, was propagated in Vero cells and clarified cell
lysates were used for Western blot analysis and ELISA. VACV
stock for challenge was prepared in L929 cells (Selin et al.,
1994) and purified from serum contaminants by centrifugation
on sucrose gradients (Chen et al., 2001). Viral titer assays were
performed on Vero cells (Selin et al., 1994).
Construction of DNA vaccines
Individual variola (VARV) genes, with modified codon usage,
were synthesized based on variola major India 1967 (VARV-IND)
sequences. Sequences of orthopoxviruses were derived from
NCBI genome database and aligned using MacVector 7.0. DNA
inserts were then subcloned into pSW3891 immediately after the
CMV immediate early (IE) promoter (Wang et al., 2005). For
VARV DNAvaccines reported in this study, an additional human
tissue plasminogen activator (tPA) sequence was used to enhance
the antigen expression based on previous reports (Wang et al.,
2006). The PCR amplified VARV genes were subcloned into the
same vector downstream of the tPA leader sequence which was
already included in the vector (Wang et al., 2004). Each DNA
vaccine plasmid transformed in E. coli (HB101 strain) was
confirmed by restriction digestion and DNA sequencing before
large amounts of DNA plasmids were prepared with a Mega
purification kit (Qiagen, Valencia, CA). In this report, VARV
antigen related vaccines are referred to as A30, B7 and F8, the
recombinant VARV proteins are referred to as rA30, rB7 and rF8,
and the VACVantigens are referred to as A27, B5 and D8.
Protein production
Histidine-tagged antigen gene sequences of vaccinia (A27,
D8, B5) or variola viruses (A30, F8, B7) were cloned into the
pET-15b vector (Invitrogen). Constructs were than transformed
into DE3 competent cells for expression. The transformed cells
were grown overnight at 37 °C and inoculated at 5% into LB
medium. The culture was grown until cell density measured at
A600 reached O.D. range of 0.6 to 1.0. Then Isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added to reach a final con-
centration 0.4–0.8 mM for the induction of protein expression.
Cells were harvested 3 h later and lysed by sonication.
Recombinant proteins were then loaded onto Ni column
(Qiagen), according to the manufacturer's recommendations.
After washing the unbound proteins with 20 mM imidazole, the
target protein was eluted by 250 mM imidazole in 8 M urea lysis
buffer. The purified proteins were refolded by dialysis against
phosphate-buffered saline. Protein concentration and purity were
determined by SDS gel.
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Six to eight week old female BALB/c mice were purchased
from Taconic Farms (Germantown, NY) and housed in the
Department of Animal Medicine at the University of
Massachusetts Medical School (UMMS) in accordance with
IACUC and IBC approved protocols. The animals were
immunized with a Helios gene gun (Bio-Rad) at the shaved
abdominal skin as previously reported (Wang et al., 2004).
Two DNA immunization schedules were used in this report
(see figure legend for details). Each mouse received 4 monthly
or 2 bi-weekly immunizations with six DNA shots of 2 μg
each per immunization. Immunogenicity was studied in 10
mice per group and each challenge study group consisted of 5
mice. The blood samples were collected peri-orbitally prior to
the first immunization and 2 weeks after each immunization.
Mice immunized with VACV received 105 pfu of VACV in
10 μl of PBS by intradermal inoculation into the ear pinnae 1
month before challenge (Tscharke et al., 2002; Tscharke and
Smith, 1999). Mice immunized with proteins received 2 bi-
weekly immunizations with purified recombinant proteins
(10 μg per injection) in PBS emulsified in Incomplete
Freund's Adjuvant.
Transient expression of antigens
293T cells were transiently transfected with a calcium
chloride co-precipitation method using 10 μg of plasmid DNA
for 2×106 cells in a 60-mm dish. Cells were harvested 72 h later.
Both supernatants and cell lysates were collected for ELISA or
Western blot assays. Supernatants from multiple dishes were
pooled and the amount of antigen was determined by Coomassie
blue staining of SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) gels.
Enzyme-linked immunosorbent assay (ELISA)
Vaccinia virus antigen-specific IgG responses in immunized
mice were measured by ELISA using individual mouse sera
from each animal group. ELISA plates were coated with 100 μl
of the antigens at 1 μg/ml harvested from 293T cells transiently
transfected with the DNA vaccine plasmids and incubated
overnight at 4 °C (Wyatt et al., 2004). Serially diluted mouse
sera (100 μl) were added to each well and assayed in duplicate
after blocking. The plates were incubated with biotinylated anti-
mouse IgG (Vector Laboratories, Burlingame, CA) diluted at
1:1000 (100 μl per well), followed by horseradish peroxidase-
conjugated streptavidin (Vector Laboratories) diluted at 1:2000
and finally developed with 3,3-,5,5-tetramethybenzidine
(Sigma-Aldrich, St. Louis, MO) solution (100 μl per well).
The reactions were stopped by adding 25 μl of 2 M H2SO4, and
the plates were read at OD450.
Western blot analysis of in vitro expressed VACV antigens
The same amount of transiently expressed antigens (10 ng of
protein) was loaded for the SDS-polyacrylamide gel electro-phoresis (SDS-PAGE), then transferred onto PVDF membranes
(Bio-Rad, Hercules, CA) and incubated overnight at 4 °C in
blocking buffer (0.2% I-block, 0.1% Tween-20 in 1× PBS).
Membranes were incubated with a 1:200 dilution of rabbit sera
immunized with the corresponding DNA vaccines. After being
washed, blots were incubated with alkaline phosphatase-
conjugated goat anti-rabbit IgG (Tropix, Bedford, MA) at
1:5000 dilution for 1 h at room temperature, and signals were
detected using a chemiluminescence Western-Light Kit (Tropix,
Bedford, MA). For the glycosylation study, peptide N-
glycosidase F, PNGaseF (New England BioLab, Beverly, MA)
was added to the denatured samples prepared from the
supernatants of transiently transfected 293T cells per manufac-
turer's specifications. After incubating overnight at 37 °C,
samples were loaded onto SDS-PAGE, and analyzed byWestern
blot as described above.
Plaque reduction neutralization assay
Fifty percent plaque reduction titer was determined by stan-
dard techniques (Frey et al., 2002). Briefly, sera from
immunized animals were heat inactivated for 30 min at 56 °C
and serial dilutions of antibodies were incubated with 50 pfu of
VACV for 1 h at 37 °C. Confluent Vero cells monolayers were
infected with antibody–virus mixtures for 1 h, washed with PBS
and incubated under liquid overlay for 2 days. Monolayers were
then stained with 0.5% of crystal violet (Sigma) for 5 min and
plaques were counted. The neutralization was calculated as the
percentage of the number of plaque counts reduced in the
testing serum per assay compared to the mean number of the
plaque counts for the three virus controls (without sera) in the
same assay.
Vaccinia virus challenge
Age matched female BALB/c mice (5 per group) were used
in all experiments. Challenges were conducted 2 weeks after the
last immunization. For IP challenge study, mice were
anesthetized intramuscularly with ketamine–xylazine (100/
10 mg/kg) and then injected, intraperitoneally, with
5×107 pfu of VACV-WR in 100 μl of PBS. For intranasal
challenge, mice were administered 5×106 pfu VACV-WR in
25 μl of PBS by intranasal inoculation. Mice were weighed and
observed daily, as previously described (Selin et al., 1994).
Death at the end of each following challenge was recorded. All
experiments were done in compliance with protocols approved
by the IACUC and IBC at UMMS.
Statistical analysis
Tests were performed using Epi Info™ software for
Windows available from CDC web site. Survival curves
were analyzed using the Kaplan–Meier test. Comparisons
between the mean percentage body-weight changes for
different groups at each day after challenge and between
mean antibody titers were performed using an unpaired, two-
tailed Student's t-test (Microsoft Excel software, version
106 P. Sakhatskyy et al. / Virology 371 (2008) 98–1072003) in consultation with a biostatistician. Significance levels
were set at pb0.05.
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